1. Pipeline Chart
2. Future Applications
● Infectious Disease Prevention
doi: 10.1128/mbio.02958-23. |
The PEDV mRNA vaccine demonstrates superior active immunization efficacy compared to commercial inactivated vaccines. |
doi: 10.1128/jvi.00535-24. |
The PDCoVS mRNA vaccine developed by our company can induce high levels of neutralizing antibodies while activating both cellular and mucosal immunity. The vaccine-induced neutralizing antibodies persist for up to three months. When administered to sows during gestation, newborn piglets acquire robust passive immunization protection. This vaccine serves as a promising candidate for the prevention and control of PDCoV, demonstrating broad application prospects. |
● Healrna’s in vivo CAR-T Technology
Our in vivo CAR-T technology can be applied to treat hematological malignancies, autoimmune diseases, and other Indications.
Treatment of Hematological Malignancies
In vivo generated CAR-T cells effectively eliminate CD19+ tumor cells. Some platforms can simultaneously engineer multiple immune cell types, broadening the therapeutic scope. Initial clinical data indicate that our in vivo BCMA-CAR-T therapy for relapsed/refractory multiple myeloma has achieved a 100% objective response rate with a favorable safety profile.
Treatment of Autoimmune Diseases
Compared to conventional ex vivo CAR-T approaches, in vivo CAR-T simplifies the production process while preserving the natural functionality of T cells. An LNP-mediated transient expression system enables controlled expression and repeatable dosing, aligning with the precise regulatory demands of autoimmune disease management. Our proprietary in vivo CAR-T technology is positioned for future applications in treating rheumatoid arthritis, systemic lupus erythematosus, and related disorders.
